Elly Gerald Stoica

Array ( [id] => 15293645 [patent_doc_number] => 20190389958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => ANTI-CXCR4 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/481148 [patent_app_country] => US [patent_app_date] => 2017-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16481148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901879 [patent_doc_number] => 20190040144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => FRIZZLED PROTEIN-BINDING AGENTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/073198 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16073198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15784957 [patent_doc_number] => 10626186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Anti-VWF D'D3 single-domain antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 16/072784 [patent_app_country] => US [patent_app_date] => 2017-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 13226 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16072784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883853 [patent_doc_number] => 20210170048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => FORMATION OF FUNCTIONALIZED NANOPARTICLES BY SUPRAMOLECULAR CO-ASSEMBLY [patent_app_type] => utility [patent_app_number] => 16/071168 [patent_app_country] => US [patent_app_date] => 2017-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16071168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15227625 [patent_doc_number] => 10501523 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => IL-8 level based method of predicting the outcome of colon cancer treatment [patent_app_type] => utility [patent_app_number] => 15/408827 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7330 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15408827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14291925 [patent_doc_number] => 10286070 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders [patent_app_type] => utility [patent_app_number] => 15/403965 [patent_app_country] => US [patent_app_date] => 2017-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 37 [patent_no_of_words] => 23980 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15403965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13790771 [patent_doc_number] => 20190008924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => COMPOSITIONS AND METHODS FOR GENERATING IMMUNOTOLERANT RESPONSES [patent_app_type] => utility [patent_app_number] => 16/068133 [patent_app_country] => US [patent_app_date] => 2017-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15290741 [patent_doc_number] => 20190388506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => FACTOR H FRAGMENT FOR USE AS AN ANTI-ANGIOGENIC AGENT [patent_app_type] => utility [patent_app_number] => 16/066963 [patent_app_country] => US [patent_app_date] => 2016-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15915389 [patent_doc_number] => 10654923 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Methods for treating medical conditions by anti-type 2 therapy [patent_app_type] => utility [patent_app_number] => 15/387324 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6545 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15387324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092545 [patent_doc_number] => 20170349639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/385528 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 60 [patent_no_of_words] => 47773 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15385528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618851 [patent_doc_number] => 20180360977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => Interleukin-15 Compositions and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/060389 [patent_app_country] => US [patent_app_date] => 2016-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16060389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514331 [patent_doc_number] => 20170081405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/368278 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 108 [patent_figures_cnt] => 108 [patent_no_of_words] => 68681 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15368278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618338 [patent_doc_number] => 20170128525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'Administration of Angiocidin for the Treatment of Cancer' [patent_app_type] => utility [patent_app_number] => 15/363119 [patent_app_country] => US [patent_app_date] => 2016-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9204 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15363119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182205 [patent_doc_number] => 10106604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Method of treating auto-inflammatory syndromes with IL-1beta antibodies related to canakinumab [patent_app_type] => utility [patent_app_number] => 15/359784 [patent_app_country] => US [patent_app_date] => 2016-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6930 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15359784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649202 [patent_doc_number] => 20170145103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'PREDICTING RESPONSE TO CANCER TREATMENT WITH FGFR2 INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/358941 [patent_app_country] => US [patent_app_date] => 2016-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 52411 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15358941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13287707 [patent_doc_number] => 10155026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-18 [patent_title] => Methods for treating pain caused by inflammation induced mechanical and/or thermal hypersensitivity [patent_app_type] => utility [patent_app_number] => 15/349651 [patent_app_country] => US [patent_app_date] => 2016-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 19 [patent_no_of_words] => 21451 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15349651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11527228 [patent_doc_number] => 20170087205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-30 [patent_title] => 'Replacement Therapy for Natriuretic Peptide Deficiencies' [patent_app_type] => utility [patent_app_number] => 15/347870 [patent_app_country] => US [patent_app_date] => 2016-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 36211 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15347870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236856 [patent_doc_number] => 20200254090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/774327 [patent_app_country] => US [patent_app_date] => 2016-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15774327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11457455 [patent_doc_number] => 20170051360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA' [patent_app_type] => utility [patent_app_number] => 15/346164 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 36887 [patent_no_of_claims] => 76 [patent_no_of_ind_claims] => 39 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15346164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11499221 [patent_doc_number] => 20170073407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'VEGF ANTAGONIST FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 15/342989 [patent_app_country] => US [patent_app_date] => 2016-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5694 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15342989 [rel_patent_id] =>[rel_patent_doc_number] =>)